Skip to main content
. 2023 Aug 30;35(4):399–407. doi: 10.21147/j.issn.1000-9604.2023.04.06

Figure 3.

Figure 3

Kaplan-Meier curve of OS for FAS population. Testing between the two treatment arms was carried out by log-rank test. In the anlotinib group and the TACE group, the 12-month OS rates were 96.3% and 97.2%, respectively (P=0.44). OS, overall survival; FAS, full analysis set; TACE, transcatheter arterial chemoembolization.